Healthcare Private Equity Returns Trailed Market in 2021-2023
Higher entry valuations and increased competition diminished performance for healthcare-focused private equity funds.
Updated on Oct. 6, 2026 in Healthcare
Live Poll
Do you trust that larger, consolidated investment funds provide better returns than specialized, boutique firms?
Healthcare private equity funds launched between 2021 and 2023 posted a 10.2% pooled internal rate of return, falling behind the 12% return achieved by the broader private equity asset class during that same period.
Why it matters
The performance lag stems from deployment during a 2021 market peak characterized by elevated entry valuations, alongside an influx of generalist firms competing for healthcare assets. This crowded deal environment has significantly compressed the sector's historical performance advantage over general market indices.
Healthcare-focused funds raised $16.2 billion in H1 2026, representing 6.1% of total private equity capital raised. While past cohorts like the 2012-2014 vintage posted a 26.8% IRR compared to 14.5% for all funds, 2026 is on track for a 50% decrease in total healthcare fund count versus 2025.
The players
Blackstone
A global alternative investment firm with a significant focus on life sciences and healthcare infrastructure.
Patient Square Capital
A dedicated healthcare-focused private equity firm managing large-scale, thematic investment vehicles.
The details
Capital in the healthcare sector is increasingly consolidating into fewer, larger funds that employ specialized, thematic strategies. Generalist private equity firms have built dedicated healthcare teams to capture deal flow, intensifying competition and driving up acquisition costs. Despite this, activity is cooling; only 11 healthcare private equity funds closed in the first half of 2026 as market conditions continue to evolve.
Timeline
2012-2014: Healthcare private equity funds historically outperformed the broader market.
2021-2023: Healthcare-focused funds trailed the performance of all private equity funds.
March 2026: Blackstone closed a $6.3 billion life sciences fund.
May 2026: Patient Square Capital closed a $4.4 billion fund.
H1 2026: Healthcare private equity captured 6.1% of total PE capital raised.
Market Landscape
This performance trend marks a departure from the superior returns generated by specialized healthcare funds during the 2012-2014 period. The sector is now adjusting to the realities of a post-2021 market peak, where increased competition has narrowed the historical performance gap.
Operators should anticipate a more disciplined investment environment as capital concentrates in larger, thematic funds rather than smaller, generalist-led efforts. Monitor upcoming fund performance disclosures to determine if current healthcare valuations begin to stabilize after the 2021 peak.
The takeaway
The era of easy healthcare outperformance driven by generalist interest has moderated as competition for premium assets intensifies. Operators should prioritize long-term efficiency metrics over valuation-driven growth models as the 2021-2023 vintage cohort works through its investment lifecycle.
Further reading
For more on the capital shifts affecting the sector, see our coverage of Healthcare.
Live Poll
Do you trust that larger, consolidated investment funds provide better returns than specialized, boutique firms?
